Skip to main content

Table 1 Patient/Treatment Characteristics

From: Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer

Variable   ACRT STRT1 STRT2 Total p-value
   (45 Gy) (60-63 Gy) (> 63 Gy)   
   n = 119 n = 90 n = 91   
Age median(range) 68(41,100) 67(44,88) 73(47,95) 69.5(41,100) < 0.001
Gender Female 48(40.3%) 43(47.8%) 50(54.9%) 141(47.0%) 0.108
  Male 71(59.7%) 47(52.2%) 41(45.1%) 159(53.0%)  
Smoking Status Never 8(6.8%) 2(2.2%) 4(4.4%) 14(4.7%) 0.224
  Quit 70(59.8%) 45(50.6%) 53(58.2%) 168(56.6%)  
  Current 39(33.3%) 42(47.2%) 34(37.4%) 115(38.7%)  
Karnofsky Performance Status score 90 3(2.5%) 5(5.6%) 6(6.6%) 14(4.7%) < 0.001
  80 35(29.4%) 58(64.4%) 40(44.0%) 133(44.3%)  
  70 47(39.5%) 23(25.6%) 38(41.8%) 108(36.0%)  
  ≤ 60 34(28.6%) 4(4.4%) 7(7.7%) 45(15.0%)  
Presenting Weight No 56(51.4%) 67(75.3%) 61(67.8%) 184(63.9%) 0.002
loss ≥ 5% Yes 53(48.6%) 22(24.7%) 29(32.2%) 104(36.1%)  
Tumor Stage IIIA 37(31.1%) 50(55.6%) 57(62.6%) 144(48.0%) < 0.001
  IIIB 82(68.9%) 40(44.4%) 34(37.4%) 156(52.0%)  
Tumor Histology Adenocarcinoma 37(31.4%) 31(35.2%) 41(45.6%) 109(36.8%) 0.142
  Squamous 42(35.6%) 34(38.6%) 32(35.6%) 108(36.5%)  
  NSC-NOS 39(33.1%) 23(26.1%) 17(18.9%) 79(26.6%)  
Tumor Grade Well 3(2.5%) 0(0%) 4(4.4%) 7(2.3%) 0.069
  Moderate 11(9.2%) 12(13.3%) 10(11.0%) 33(11.0%)  
  Poor 37(31.1%) 42(46.7%) 29(31.9%) 108(36.0%)  
  Unclear 68(57.1%) 36(40.0%) 48(52.7%) 152(50.7%)  
Tumor Size (cm) median(range) 5(1,11.5) 5(1.5,10.5) 4.2(1,9) 5(1,11.5) 0.039
Induction No 96(80.7%) 29(32.2%) 64(70.3%) 189(63.0%) < 0.001
Chemotherapy Yes 23(19.3%) 61(67.8%) 27(29.7%) 111(37.0%)  
Adjuvant No 105(88.2%) 85(94.4%) 86(94.5%) 276(92.0%) 0.15
Chemotherapy Yes 14(11.8%) 5(5.6%) 5(5.5%) 24(8.0%)  
  1. ACRT: accelerated radiotherapy; STRT1: standard radiation therapy 1 (60-63 Gy); SBRT2: standard radiation therapy 2 (> 63 Gy); NSC-NOS: Non-Small Cell-Not Otherwise Specified